Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 % in institutional database with asunercept plus standard of care in newly diagnosed glioblastoma multiforme patients
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
